相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma
Enrico Maffini et al.
HAEMATOLOGICA (2019)
Chimeric antigen receptor T cell persistence and memory cell formation
Alexander D. McLellan et al.
IMMUNOLOGY AND CELL BIOLOGY (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model
Shyril O'Steen et al.
BLOOD (2019)
Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma
Luisa Giaccone et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta et al.
NATURE MEDICINE (2018)
Genomic complexity of multiple myeloma and its clinical implications
Salomon Manier et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma
Damian J. Green et al.
BLOOD ADVANCES (2017)
Allogeneic stem cell transplantation for multiple myeloma: is there a future?
B. Dhakal et al.
BONE MARROW TRANSPLANTATION (2016)
The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma
Wilson I. Gonsalves et al.
LEUKEMIA RESEARCH (2016)
Target Antigen Density Governs the Efficacy of Anti-CD20-CD28-CD3 ζ Chimeric Antigen Receptor-Modified Effector CD8+ T Cells
Keisuke Watanabe et al.
JOURNAL OF IMMUNOLOGY (2015)
A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma
W. I. Bensinger et al.
BONE MARROW TRANSPLANTATION (2014)
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
Joel Crespo et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire
Damien Roos-Weil et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting
Marcello Rotta et al.
BLOOD (2009)
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome
John M. Pagel et al.
BLOOD (2009)
Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (ZevalinA®)
C. Chiesa et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
Reduced-intensity conditioning for myeloma:: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning
Charles Crawley et al.
BLOOD (2007)
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission
JM Pagel et al.
BLOOD (2006)
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma:: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT
C Crawley et al.
BLOOD (2005)
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma
DG Maloney et al.
BLOOD (2003)
分享论文
